NCT06207006 E-intervention on Subclinical Fear of Cancer Recurrence
| NCT ID | NCT06207006 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2024-05-02 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2024-05-02 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.
Eligibility Criteria
Inclusion Criteria: * Cantonese- or Mandarin-speaking Chinese cancer survivors * recently diagnosed with potentially curable (stage 0 to III) colorectal or breast cancer * had recently completed surgery as primary treatment * have completed hospital-based adjuvant treatments (including radiotherapy and chemotherapy) within the past six months * scored 13 to 21 on the fear of cancer recurrence-short form will be recruited. Exclusion Criteria: * non-Chinese ethnicity * metastatic cancer * with current diagnosis of depression or psychosis or are currently receiving psychological treatments * language or intellectual difficulties that prevent them from understanding the intervention content * having limited or no Internet access.
Contact & Investigator
Danielle Ng, PhD
PRINCIPAL INVESTIGATOR
School of Public Health, The University of Hong Kong
Frequently Asked Questions
Who can join the NCT06207006 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06207006 currently recruiting?
Yes, NCT06207006 is actively recruiting participants. Contact the research team at dwlng@hku.hk for enrollment information.
Where is the NCT06207006 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06207006 clinical trial?
NCT06207006 is sponsored by The University of Hong Kong. The principal investigator is Danielle Ng, PhD at School of Public Health, The University of Hong Kong. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.